Analysts Issue Forecasts for Genmab A/S FY2027 Earnings

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright raised their FY2027 earnings per share estimates for shares of Genmab A/S in a research report issued to clients and investors on Wednesday, October 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $1.59 for the year, up from their prior forecast of $1.48. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.21 per share.

A number of other brokerages also recently commented on GMAB. Guggenheim upped their price objective on shares of Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. New Street Research set a $43.00 price objective on Genmab A/S in a report on Wednesday, July 22nd. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and increased their target price for the stock from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, Truist Financial increased their price objective on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average price target of $42.50.

Genmab A/S Price Performance

Shares of GMAB opened at $36.65 on Thursday. The company has a market capitalization of $22.87 billion, a price-to-earnings ratio of 28.86, a price-to-earnings-growth ratio of 2.05 and a beta of 0.81. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $40.17. The firm has a 50-day simple moving average of $33.30 and a 200-day simple moving average of $29.22. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GMAB. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after buying an additional 921,700 shares during the period. SummitTX Capital L.P. acquired a new position in Genmab A/S in the first quarter valued at $2,263,000. Finally, Ishara Investments LP purchased a new stake in Genmab A/S during the fourth quarter valued at about $2,156,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.